Kairasec Tafla 8 mg Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 8 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 8 mg

Kairasec Tafla 16 mg Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 16 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 16 mg

Kairasec Tafla 32 mg Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 32 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg

Valsartan Jubilant Filmuhúðuð tafla 80 mg Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan jubilant filmuhúðuð tafla 80 mg

jubilant pharmaceuticals nv - valsartanum inn - filmuhúðuð tafla - 80 mg

Valsartan Jubilant Filmuhúðuð tafla 160 mg Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan jubilant filmuhúðuð tafla 160 mg

jubilant pharmaceuticals nv - valsartanum inn - filmuhúðuð tafla - 160 mg

Suliqua Uniunea Europeană - islandeză - EMA (European Medicines Agency)

suliqua

sanofi winthrop industrie - insúlín glargine, lixisenatide - sykursýki, tegund 2 - lyf notuð við sykursýki - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Lyxumia Uniunea Europeană - islandeză - EMA (European Medicines Agency)

lyxumia

sanofi winthrop industrie - lixisenatíð - sykursýki, tegund 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Onduarp Uniunea Europeană - islandeză - EMA (European Medicines Agency)

onduarp

boehringer ingelheim international gmbh - telmisartan - háþrýstingur - hjarta og æðakerfi - meðferð háþrýstingi í fullorðnir:bæta á therapyonduarp er ætlað í fullorðnir sem blóðþrýstingur er ekki nægilega stjórn á meðferð. skipti therapyadult sjúklingar fá efnaskipti og meðferð frá sér töflur getur stað fá töflur onduarp inniheldur sama hluti skömmtum.

Enviage Uniunea Europeană - islandeză - EMA (European Medicines Agency)

enviage

novartis europharm ltd. - aliskiren - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - meðferð við nauðsynlegum háþrýstingi.